Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Molecules (Basel, Switzerland)|February 15, 2022
Flavonoids: Antiplatelet Effect as Inhibitors of COX-1Cristina Zaragozá, Miguel Ángel Álvarez-Mon, Francisco Zaragozá, et al.
Family Practice|October 7, 2017
Maintained effect of a training program on attitudes towards depression in family physiciansRicardo Manzanera, Guillermo Lahera, Miguel Ángel Álvarez-Mon, et al.
Child and Adolescent Psychiatric Clinics of North America|June 13, 2022
Addressing the Treatment and Service Needs of Young Adults with Attention Deficit Hyperactivity DisorderJavier Quintero, Alberto Rodríguez-Quiroga, Miguel Ángel Álvarez-Mon, et al.
Health Care Transitions|December 22, 2025
Diagnostic stability of attention deficit hyperactivity disorder during healthcare transitionAlberto Rodríguez-Quiroga, Cristina Bonilla Sanz, Miguel Ángel Álvarez-Mon, et al.
The British Journal of Psychiatry : the Journal of Mental Science|January 7, 2025
Attitudes towards mental health professionals in social media: infodemiology studyHarriet Battle, Miguel Ángel Álvarez-Mon, Francisco J Lara-Abelenda, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 6, 2021
Binding and antiplatelet activity of quercetin, rutin, diosmetin, and diosmin flavonoidsCristina Zaragozá, Jorge Monserrat, Carolina Mantecón, et al.
Revista De Psiquiatria Y Salud Mental|December 4, 2021
Obsessive-compulsive symptoms in anxiety and depressive disorders: Influence of recent and/or traumatic life eventsArantxa Orozco, Narcís Cardoner, Cristina F Aragón, et al.
Journal of Clinical Medicine|July 27, 2022
Postpartum Relapse in Patients with Bipolar DisorderJavier Conejo-Galindo, Alejandro Sanz-Giancola, Miguel Ángel Álvarez-Mon, et al.
Revista De Psiquiatria Y Salud Mental|December 28, 2020
Obsessive-compulsive symptoms in anxiety and depressive disorders: Influence of recent and/or traumatic life eventsArantxa Orozco, Narcís Cardoner, Cristina F Aragón, et al.
Frontiers in Pharmacology|February 24, 2025
Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectivenessNarcis Cardoner, Luis Gutiérrez-Rojas, Pilar Saiz, et al.
Pageof 3